Industry P pharmaphorum
UEGW delegates hear of strides forward in IBD treatment
UEGW delegates hear of strides forward in IBD treatment Phil.Taylor Wed, 21/10/2026 - 09:36
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry P pharmaphorum
UEGW delegates hear of strides forward in IBD treatment Phil.Taylor Wed, 21/10/2026 - 09:36
Industry
Clinical Trials Arena
Patients treated with Shionogi & F2G’s invasive aspergillosis drug were released from hospital sooner than those in the comparator arm. The post Shionogi and F2G’s invasive aspergillosis drug shows long-term benefit appeared first on Clinical Trials Arena.
Regulatory
Pharmaceutical Technology
The market withdrawal caps a tumultuous few years for the chikungunya vaccine amid related adverse events.
Manufacturing B BioTechniques
Amsbio (Oxford, UK) announce StemFit™ Basic05, a next-generation, animal origin-free medium designed for scalable human pluripotent stem cell (hPSC) manufacturing. Compatible with both 2D adherent and 3D suspension culture, this unique cell culture medium enables a streamlined wo…
Clinical
Clinical Trials Arena
AstraZeneca and Oracle have partnered to investigate how AI and real-world data can help medical teams recruit eligible clinical trial candidates. The post AstraZeneca and Oracle collaborate to test AI in clinical trial recruitment appeared first on Clinical Trials Arena.
Industry
Pharmaceutical Technology
Sanofi has signed a global licensing and strategic collaboration agreement with UK-based biotechnology firm ScionxBio to develop long-acting mRNA therapies using the TERA platform.
Regulatory
STAT Biotech
After a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma.
Industry
STAT Biotech
Mark Cuban's Cost Plus Drugs says it can reduce manufacturing costs for custom rare disease drugs and n-of-1 gene therapies.
Industry
MHRA
Patients across Great Britain will have continued access to medical devices and in vitro diagnostic devices (IVDs) already approved for the EU market.
Industry E EMBL
EMBL-EBI’s new Genomics Technology Infrastructure Team Leader discusses how the Ensembl platform is keeping pace with the genomic data deluge.
Industry P Pharmafile
Claris Biotherapeutics has reported visual acuity improvements with its experimental therapy CSB-001 in a proof-of-concept study involving patients with limbal stem cell deficiency (LSCD), a rare eye-surface disorder that can cause severe vision loss or blindness. Data presented…
Industry
Labiotech
Medicines are under review in the clinic to treat myopia. Here are five myopia companies in sight of approval for their therapies. The post Shifting the standard: myopia companies to look out for appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unautho…
Industry P pharmaphorum
The pre-commercial case for connecting data before acquiring more Nicole.Raleigh Wed, 21/10/2026 - 07:00
Clinical S Science News
Grant from Advanced Research Projects Agency for Health will expand testing of supplements and approved drugs to prevent dementia in people at risk
Clinical P Pharmaceutical Executive
Webinar Date/Time: Thu, Oct 29, 2026 12:00 PM EDT
Industry B BioPharm International
Webinar Date/Time: Thursday, October 22, 2026 11:00 AM EDT
Industry I In the Pipeline
Here’s one of those disturbing-but-not-necessarily-surprising reports about the state of the literature. In this case, the preprint linked is the result of a deliberate search for papers that are working with a list of twenty cell lines that have clear genetic deletions and/or mu…
Clinical
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTTIGERMED’S TAKE ON RUNNING TRIALS IN THE U.S. AND CHINABritney Winterberger on parallel U.S.-China development strategies, IITs, and easing friction in clinical development
Industry S Science News
With high-speed cameras and a “pitch cannon,” researchers are refining the automated ball-strike system about to call its first World Series
Regulatory
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTGSK’S JEMPERLI GAINS RECTAL CANCER APPROVAL AS RIVALS ADVANCE ACROSS COLORECTAL SETTINGSSurgery-sparing treatment gains accelerated approval as ESMO data broaden the evidence for checkpoint inhibitors in related settings
Regulatory
Nature Reviews Drug Discovery
Research
Nature Biotechnology
Research N Nature Medicine
Industry N Nature Medicine
Research N Nature Medicine
Industry
Nature Biotechnology
Clinical N Nature Medicine
Industry N Nature Medicine
Industry
BioCentury
BIOCENTURY | DATA BYTECHINA IS GROWING ITS FIRST-IN-CLASS FOOTPRINTMore than 40% of China’s deals this year are for programs with first-in-class potential, the highest share in at least four years
Manufacturing B BioProcess International
We spoke with a biotech CEO who said, “Australia is increasingly focused not just on creating great science, but on building the infrastructure needed to turn that science into globally scalable products.”
Industry
GEN
Newly developed palladium-coated membranes capture PFAS and use reactive hydrogen to break their carbon–fluorine bonds. During 58 days of continuous operation, the system achieved up to 96% removal and 83% defluorination. The post New Catalytic Reactive-Hydrogen Membranes Capture…
Industry
BioCentury
BIOCENTURY | MANAGEMENT TRACKSIRONWOOD PROMOTING COMMERCIAL CHIEF IN PLANNED CEO SUCCESSIONPlus: Former Novo CEO to become Lundbeck’s chair; FDA official takes position amid BetaNova merger; and more
Industry
BioCentury
BIOCENTURY | FINANCESTOFFELS TURNS TO INDIAN PHARMA TO REVIVE CAR T PROGRAMSMankind’s majority investment backs start-up Armed Cell amid weak VC appetite for cell therapy companies
Clinical B BioPharm International
Nano24’s inhaled exosome therapy reduces mortality in a phase 2b ARDS trial, the FDA grants fast track designation to Nuravax’s preventive Alzheimer vaccine, and Bionyra’s long-acting anti-TL1A antibody shows a half-life that could support dosing every 3 to 6 months.
Industry
Fierce Pharma
Building a Pragmatic E&L Framework for New Modalities Explore how a science-driven, phase-appropriate E&L strategy can help protect patient safety, improve operational efficiency and support innovation in new modality manufacturing. smarcus Tue, 10/20/2026 - 16:33 Explore…
Regulatory
FDA Press Announcements
FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.
Industry
GEN
The companies' strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Hansoh’s ADC technology platform. The post Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration a…
Industry
GEN
The partners are targeting NGS core labs with a combined offering that automates next-generation sequencing library prep workflows using kits from Takara Bio and SPT Labtech’s firefly instrument. They are starting with RNA-seq with plans to expand. The post Takara Bio USA, SPT La…
Regulatory
MedCity News
The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular genetic signature. It’s a label expansion for Jemperli, which was initially approved as a treatment for endometrial cancer The post GSK Immunotherapy Gets Acc…
Industry
Inside Precision Medicine
Research suggests a type of low-intensity targeted ultrasound could be an effective treatment for delusions in people with schizophrenia or schizoaffective disorder. The post Targeted Brain Ultrasound Could Help Relieve Schizophrenia Symptoms appeared first on Inside Precision Me…